Roche announces collaboration with Lilly to enhance early diagnosis of Alzheimer's disease
Frontiers | Diagnostic Accuracy of Blood-Based Biomarker Panels: A Systematic Review
Predicting clinical decline and conversion to Alzheimer's disease or dementia using novel Elecsys Aβ(1–42), pTau and tTau CSF immunoassays | Scientific Reports
PDF) Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging
Roche announces collaboration with Lilly to enhance early diagnosis of Alzheimer's disease
An accurate fully automated panel of plasma biomarkers for Alzheimer's disease - Palmqvist - Alzheimer's & Dementia - Wiley Online Library
Roche's Elecsys Amyloid Plasma Panel granted FDA Breakthrough Device Designation - MedTechAsia
Elecsys® β-Amyloid(1-42) CSF II
Method comparison study of the Elecsys® β-Amyloid (1–42) CSF assay versus comparator assays and LC-MS/MS - ScienceDirect
Roche Joins Hand With Lilly To Improve Early Diagnosis Of Alzheimer's Disease
Roche bags USFDA Breakthrough Device Designation for Elecsys Amyloid Plasma Panel for early detection of Alzheimer's disease
FDA Grants Breakthrough Device Designation for Roche Alzheimer's Early-Detection Solution | Clinical Lab Products
Roche Alzheimer's disease Cerebrospinal Fluid (CSF) assays receive FDA clearance, supporting more accurate and timely diagnosis
Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer's disease | Nature Medicine
Roche, Eli Lilly team up on Alzheimer's blood test
Roche's Alzheimer's Early Detection Test Earns Breakthrough Nod | Medical Product Outsourcing
Roche colabora con Lilly en la mejora del diagnóstico precoz de la enfermedad de Alzheimer | NGD - Noticias y Gestión de la Dependencia
Roche bags USFDA Breakthrough Device Designation for Elecsys Amyloid Plasma Panel for early detection of Alzheimer's disease
Roche, Lilly partner on early diagnosis of Alzheimer's disease | LabPulse.com
US FDA approves Roche's two Elecsys CSF assays to detect Alzheimer's
PDF) Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease-Related β-Amyloid Status
Confounding factors of Alzheimer's disease plasma biomarkers and their impact on clinical performance | medRxiv
Roche's Elecsys Amyloid Plasma Panel Granted FDA Breakthrough Device Designation to Enable a Timely Diagnosis of Alzheimer's Disease
